Low-dose Emicizumab prophylaxis in severe haemophilia A patients -a retrospective study bringing new hope for our patients

CONCLUSION: Low-dose Emicizumab offers a cost effective treatment option and can improve access in developing countries. These findings need to be confirmed in a larger and better controlled study.PMID:38160726 | DOI:10.1016/j.jtha.2023.12.023

Source: Thrombosis and Haemostasis - December 31, 2023 Category: Hematology Authors: Rucha Patil Chandrakala Shanmukhaiah Nithya J Gogtay Puloma Pandey Kirti Patil Farah Jijina Manisha Madkaikar Source Type: research